BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ

$7.59

+$0.02 (0.33%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$7.43$7.92

Open $7.63

52 Week Range

$6.00$11.31

Previous Close $7.57

Market Cap1.60B

Volume4.40M

Avg Volume4.99M

P/E (TTM)-181.83

EPS (TTM)$-0.04

Dividend / YieldN/A

Dividend StreakN/A

Latest News for BioCryst Pharmaceuticals, Inc.

DEC13

Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Alkeon Capital Management LLC lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 20.8% during the undefined quarter, according to the company in its most recent filing with the Secu...

defenseworld.net•3 days ago

DEC12

FDA expands approval of BioCryst's rare disease drug for use in young children

The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to un...

reuters.com•3 days ago

DEC12

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and s...

globenewswire.com•3 days ago

DEC4

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted f...

globenewswire.com•11 days ago

DEC3

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Har...

globenewswire.com•12 days ago

DEC3

Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Fisher Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 8.8% during the second quarter, according to the company in its most recent disclosure with the S...

defenseworld.net•13 days ago

NOV30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis s...

seekingalpha.com•16 days ago

NOV26

BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Merck KGaA (OTCMKTS:MKKGY) Financial Contrast

Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two busin...

defenseworld.net•20 days ago

NOV24

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - Presid...

seekingalpha.com•21 days ago

NOV6

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustai...

globenewswire.com•39 days ago